Back to Search
Start Over
5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON.
- Source :
-
Annals of Oncology . 2022 Supplement 2, Vol. 33, pS29-S30. 2p. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 155963100
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.02.014